Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Verapamil and the TXNIP–Bone Turnover Link
2026-10-12
A 2025 study examined whether verapamil’s reported suppression of TXNIP could be relevant to osteoporosis. Combining a Chinese genetic association analysis with cell-based mechanistic work and an ovariectomy-induced mouse model, the authors linked TXNIP-related signaling to bone turnover and reported reduced bone loss after verapamil exposure in mice. The findings are hypothesis-generating rather than evidence of clinical efficacy.
-
Sodium Oxamate: What the ICH Study Shows
2026-10-12
A 2026 mouse study suggests that lactate-linked H3K18 lactylation in microglia may support white-matter repair after intracerebral hemorrhage. Its divergent findings with Oxamate and p300/CBP inhibition caution against treating LDH-A inhibition, lactate reduction, and histone-lactylation blockade as interchangeable—and do not establish cancer or clinical efficacy.
-
Klotho mRNA and Cellular Rejuvenation: An Appraisal
2026-10-11
A 2026 preclinical study reports that engineered Klotho mRNA reduced senescence-associated phenotypes in aged and Klotho-deficient induced mesenchymal stem cells. The evidence is promising but remains limited to cellular models, short-term molecular and functional readouts, and the study record supplied here does not establish therapeutic benefit in animals or humans.
-
PFPD Nanorods Activate STING via Nuclear DNA Damage
2026-10-10
The 2024 Journal of Controlled Release study presents PFPD, nuclear-targeted chimeric peptide nanorods that combine a photosensitizer with the STING agonist DMXAA (Vadimezan). By linking light-triggered nuclear DNA damage to cGAS/STING signaling, the platform enhanced innate immune activation and suppressed lung metastatic tumors in the reported preclinical models.
-
Pyridostatin: From G4 Stabilization to Evidence
2026-10-09
Pyridostatin and Pyridostatin TFA are useful chemical probes for studying G-quadruplex biology. This article explains how to interpret their effects across telomere, cancer, and TDP-43 research while separating direct evidence from carefully bounded scientific inference.
-
Single-Cell Insights into A. baumannii Biofilms
2026-10-09
A 2026 journal pre-proof uses single-cell RNA sequencing and pseudotemporal analysis to examine how Acinetobacter baumannii transitions from planktonic growth to mature biofilm states. The study reports increasing transcriptional heterogeneity, metabolic divergence, stress adaptation, nutrient-scavenging programs, and a trajectory-associated state transition. Its findings are valuable for hypothesis generation, but they do not by themselves establish causality, clinical relevance, or validated therapeutic targets.
-
KRAS Phase Separation in Colon Cancer
2026-10-08
Wang et al. report that farnesylation at KRAS C185 promotes cytoplasmic condensates that organize RCE1-dependent KRAS processing, membrane localization, and signaling in colon cancer. The findings connect KRAS lipid modification with phase separation and suggest that disrupting this process may improve the activity of G12C inhibitors, although the evidence remains primarily mechanistic and preclinical.
-
Amorolfine Hydrochloride and Ploidy Stress
2026-10-08
A source-grounded overview of how budding-yeast ploidy, cell-surface integrity and ergosterol-related gene expression inform conceptual research involving Amorolfine Hydrochloride, while distinguishing published evidence from supplier claims and translational speculation.
-
Hexamethonium Bromide in Autonomic Research
2026-10-07
A source-grounded overview of Hexamethonium Bromide as a research probe for autonomic ganglia, using sex differences in angiotensin II-induced hypertension to assess what ganglionic blockade can—and cannot—show about sympathetic regulation, baroreflex function, and translational relevance.
-
7-Ethyl-10-hydroxycamptothecin: Evidence Map
2026-10-07
Explore how 7-Ethyl-10-hydroxycamptothecin, also known as SN-38, connects topoisomerase I inhibition with FUBP1–FUSE biology. This evidence-focused analysis separates established findings, mechanistic interpretation, and the limits of translating colon cancer research data.
-
Sulfamonomethoxine and Soft Tunic Syndrome
2026-10-06
Park et al. evaluated 20 compounds against Azumiobodo hoyamushi, linking in vitro parasite-killing estimates with observations in experimentally infected ascidians. Sulfamonomethoxine showed comparatively low activity in the reported screening framework, while formalin and chlorine dioxide produced the clearest reduction in parasite burden in the host model.
-
ECL Western Blotting Substrate: Product Overview
2026-10-06
ECL Western Blotting Substrate (SKU K2187) is described by APExBIO as a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent Western blot imaging. No matched paper evidence was provided, so performance claims and broader applicability remain unverified.
-
(-)-Blebbistatin and Mechanomemory: 5 Key Questions
2026-10-05
A source-grounded guide to how (-)-Blebbistatin relates to actomyosin-dependent mechanotransduction, what current evidence shows, and where interpretation must remain cautious.
-
OPP in B-Cell Protein Synthesis Research
2026-10-05
O-propargyl-puromycin (OPP) is a conceptual tool for measuring nascent protein production in cells. This overview explains how OPP could complement recent findings linking Pcbp1, mitochondrial integrity, translation, and antibody responses in B cells, while distinguishing published evidence from proposed applications and identifying important limitations.
-
ERK5 Signaling in Vitamin D–Driven AML Differentiation
2026-10-04
Wang et al. identify the MEK5–ERK5 pathway as a distinct regulator of 1α,25-(OH)2 vitamin D3-induced differentiation and cell-cycle arrest in AML cell lines. Their findings show that ERK5 and canonical ERK1/2 signaling can produce different, even opposing, effects on myeloid maturation, providing a framework for pathway-selective interpretation.